Cited by 103Diabetes and associated disordersDiabetes Management and ResearchT-cell and B-cell Immunology

Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study

Open access
Vehik, Kendra, Lynch, Kristian F., Schatz, Desmond A., Akolkar, Beena, Hagopian, William, Rewers, Marian, She, Jin-Xiong, Simell, Olli +6 more·2016·Diabetes Care

Abstract

OBJECTIVE: β-Cell autoantibodies are a feature of the preclinical phase of type 1 diabetes. Here, we asked how frequently they revert in a cohort of children at risk for type 1 diabetes and whether reversion has any effect on type 1 diabetes risk. RESEARCH DESIGN AND METHODS: Children were up to 10 years of age and screened more than once for insulin autoantibody, GAD antibody, and insulinoma antigen-2 antibodies. Persistent autoantibody was defined as an autoantibody present on two or more consecutive visits and confirmed in two reference laboratories. Reversion was defined as two or more consecutive negative visits after persistence. Time-dependent Cox regression was used to examine how reversion modified the risk of development of multiple autoantibodies and type 1 diabetes. RESULTS: Reversion was relatively frequent for autoantibodies to GAD65 (19%) and insulin (29%), but was largely restricted to children who had single autoantibodies (24%) and rare in children who had developed multiple autoantibodies (<1%). Most (85%) reversion of single autoantibodies occurred within 2 years of seroconversion. Reversion was associated with HLA genotype, age, and decreasing titer. Children who reverted from single autoantibodies to autoantibody negative had, from birth, a risk for type 1 diabetes of 0.14 per 100 person-years; children who never developed autoantibodies, 0.06 per 100 person-years; and, children who remained single-autoantibody positive, 1.8 per 100 person-years. CONCLUSIONS: Type 1 diabetes risk remained high in children who had developed multiple β-cell autoantibodies even when individual autoantibodies reverted. We suggest that monitoring children with single autoantibodies for at least 1 year after seroconversion is beneficial for stratification of type 1 diabetes risk.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc16-0181

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In several cohort studies, up to 50% of children with only a single autoantibody revert to being islet autoantibody negative during follow-up.

    “In several cohort studies, up to 50% of children with only a single autoantibody revert to being islet autoantibody negative during follow-up (79,80).”

    From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [80]

    The available passages are contributor lists and committee descriptions (The Teddy Study Group, p. 1; Supplementary Data, p. 2), not findings on autoantibody reversion. Searches for single-autoantibody reversion and 50% returned no passage reporting a reversion rate; the decisive study text may be missing from our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vehik, K., Lynch, K. F., Schatz, D. A., Akolkar, B., Hagopian, W., Rewers, M., She, J.-X., Simell, O., Toppari, J., Ziegler, A.-G., Lernmark, Å., Bonifacio, E., Krischer, J. P., & the TEDDY Study Group
Affiliations
  • University of South Florida (US)
  • University of Florida (US)
  • National Institute of Diabetes and Digestive and Kidney Diseases (US)
  • Pacific Northwest Research Institute (US)
  • University of Colorado Health (US)
  • Augusta University (US)
  • Turku University Hospital (FI)
  • TUM Klinikum (DE)
  • Lund University (SE)
  • German Center for Diabetes Research (DE)
Corresponding author
Vehik, Kendra
Venue
Diabetes Care
Published
2016-06-16
Volume
39
Issue
9
Pages
1535-1542
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2438883383
Cited by
103
References
27
Citations by year
2026: 15 · 2025: 14 · 2024: 17 · 2023: 10 · 2022: 7 · 2021: 9 · 2020: 8 · 2019: 6 · 2018: 6 · 2017: 6 · 2016: 5
FWCI
6.19
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Site cant be reached (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-63829, U01-DK-63861, U01-DK-63821, U01-DK-63865, U01-DK-63863, U01-DK-63836, U01-DK-63790, Contract No. HHSN267200700014C)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
type 1 diabetes, islet autoimmunity, insulin autoantibodies, GAD65 antibodies, preclinical type 1 diabetes, type 1 diabetes risk, seroconversion, HLA genotypes, vulnerable children, TEDDY study
MeSH terms
Seroconversion, Autoantibodies, Child, Child, Preschool, Diabetes Mellitus, Type 1, Female, Genotype, Glutamate Decarboxylase, Humans, Insulin, Insulin Antibodies, Male, Prospective Studies, Risk Factors, Autoimmunity, Risk Assessment, Insulin-Secreting Cells, Receptor-Like Protein Tyrosine Phosphatases, Class 8

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review